Blaze Bioscience Announces Enrollment is Complete on its Pivotal Phase 2/3 Trial of tozuleristide and the CanvasTM Imaging System in Pediatric Central Nervous System Tumors November 2, 2022

Blaze Bioscience Announces FDA has Granted Fast Track Designation to BLZ-100 (tozuleristide) for Pediatric Central Nervous System Tumors
April 7, 2020

Blaze Bioscience Announces the Publication of Phase 1 Clinical Trial Results for Tumor Paint: BLZ-100 (tozuleristide) in Adults with Glioma
May 9, 2019